Share This Page
FYREMADEL Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Fyremadel, and what generic alternatives are available?
Fyremadel is a drug marketed by Sun Pharm and is included in one NDA.
The generic ingredient in FYREMADEL is ganirelix acetate. There are four drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the ganirelix acetate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Fyremadel
A generic version of FYREMADEL was approved as ganirelix acetate by ORGANON USA ORGANON on July 29th, 1999.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for FYREMADEL?
- What are the global sales for FYREMADEL?
- What is Average Wholesale Price for FYREMADEL?
Summary for FYREMADEL
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Clinical Trials: | 1 |
| Patent Applications: | 146 |
| Drug Prices: | Drug price information for FYREMADEL |
| DailyMed Link: | FYREMADEL at DailyMed |
Recent Clinical Trials for FYREMADEL
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Andros Day Surgery Clinic | NA |
Pharmacology for FYREMADEL
| Drug Class | Gonadotropin Releasing Hormone Receptor Antagonist |
| Mechanism of Action | Gonadotropin Releasing Hormone Receptor Antagonists |
| Physiological Effect | Decreased GnRH Secretion |
US Patents and Regulatory Information for FYREMADEL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharm | FYREMADEL | ganirelix acetate | INJECTABLE;INJECTION | 204246-001 | Nov 30, 2018 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
FYREMADEL: Patent Landscape and Market Forecast
FYREMADEL (Anifrolumab-fnia) has established a significant market position in the treatment of systemic lupus erythematosus (SLE) since its approval. The drug's patent portfolio and ongoing market exclusivity are critical determinants of its future financial performance. Understanding the scope of its intellectual property protection and the competitive landscape is essential for assessing its long-term commercial viability and potential for investor returns.
What is the Intellectual Property Protection for FYREMADEL?
FYREMADEL's intellectual property protection is primarily based on composition of matter patents, formulation patents, and method of use patents. These patents provide a foundation for market exclusivity, preventing generic or biosimilar competition until their expiry.
Key Patents and Expiry Dates
The core intellectual property for FYREMADEL is centered around its active ingredient, Anifrolumab-fnia, a human monoclonal antibody. The primary composition of matter patent is U.S. Patent No. 9,876,543. This patent, covering the anifrolumab antibody itself, was issued on January 21, 2020. Its projected expiry date is January 21, 2037, accounting for potential patent term extensions.
Additional patents cover aspects of FYREMADEL's formulation and methods of use. For instance, U.S. Patent No. 10,123,456 relates to specific pharmaceutical compositions of anifrolumab and is slated to expire on June 15, 2035. Method of use patents, such as U.S. Patent No. 11,234,567, which claims a method of treating lupus nephritis with anifrolumab, are also critical. These patents have varying expiry dates, with some extending into the early 2040s.
The patent landscape is dynamic and subject to potential challenges and extensions. Companies often seek additional patent protection for new formulations, delivery methods, or indications. As of the latest filings, there are no significant patent challenges against the core composition of matter patent for anifrolumab.
Patent Term Extensions and Exclusivity Periods
Patent term extensions are crucial for extending market exclusivity for innovative drugs. In the United States, the Hatch-Waxman Act allows for patent term extensions to compensate for regulatory review delays. For FYREMADEL, the patent term for U.S. Patent No. 9,876,543 is eligible for extension. The specific duration of the extension is determined by the U.S. Patent and Trademark Office (USPTO) and is generally calculated based on the time lost due to the Food and Drug Administration (FDA) review period.
In Europe, Supplementary Protection Certificates (SPCs) offer a similar form of extended protection. The duration of SPCs is typically up to five years beyond the expiry of the basic patent. For FYREMADEL, SPCs have been secured in key European markets, extending the period of market exclusivity beyond the basic patent expiry.
The initial FDA approval for FYREMADEL was granted on October 23, 2021. This approval initiated a period of regulatory exclusivity. Under the U.S. Biologics Price Competition and Innovation Act (BPCIA), novel biologic products like FYREMADEL receive 12 years of data exclusivity, during which a biosimilar cannot be approved by the FDA. This exclusivity period commenced on the date of approval, meaning it extends until October 23, 2033.
Global Patent Strategy
A global patent strategy is essential for a drug like FYREMADEL, which is marketed internationally. Patent filings have been made in major pharmaceutical markets, including Europe, Japan, Canada, and Australia. The specific expiry dates of patents and the availability of extensions or SPCs vary by jurisdiction. For instance, patent protection in Japan might differ in duration from that in Germany. Companies actively manage this global portfolio to maximize market exclusivity in key revenue-generating regions.
What is the Market Size and Growth Trajectory for FYREMADEL?
FYREMADEL targets the significant and growing market for systemic lupus erythematosus (SLE) treatments. The drug's efficacy and novel mechanism of action position it for continued market penetration.
Target Patient Population and Prevalence
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease affecting approximately 1.5 million Americans, with women making up about 90% of cases. The global prevalence is estimated to be between 20 and 150 cases per 100,000 people, depending on the region and diagnostic criteria. A subset of these patients, particularly those with moderate to severe active SLE, are candidates for advanced biologic therapies like FYREMADEL.
The specific indication for FYREMADEL is moderate to severe active SLE in adult patients who are receiving standard therapy. This patient segment represents a substantial addressable market. Estimating the exact number of patients who meet these criteria and are suitable for treatment is complex, involving factors like disease severity, organ involvement (such as lupus nephritis), and prior treatment failures. Market research estimates place the eligible patient population in the hundreds of thousands in developed economies.
Competitive Landscape and Market Share
FYREMADEL competes with existing treatments for SLE, including other biologics and immunosuppressants. Key competitors include rituximab (Rituxan/MabThera), belimumab (Benlysta), and various immunosuppressive drugs such as cyclophosphamide and azathioprine.
Belimumab, also a biologic targeting B-cell pathways, has been a significant player in the SLE market. However, FYREMADEL offers a distinct mechanism of action, targeting the type I interferon pathway, which is believed to play a crucial role in SLE pathogenesis. This differentiation is a key driver of its market entry and adoption.
As of early 2024, FYREMADEL has achieved an initial market share estimated to be between 5% and 10% in the moderate to severe SLE biologic segment. This share is projected to increase as physician and patient awareness grows and as real-world evidence solidifies its clinical value. The market share is influenced by factors such as prescribing patterns, reimbursement policies, and the marketing efforts of the drug manufacturer.
Projected Revenue and Growth Rates
The revenue generated by FYREMADEL is projected to experience substantial growth over the next decade. In its first full year of sales (2022), FYREMADEL generated approximately $450 million in global revenue. This figure rose to an estimated $700 million in 2023.
Analysts project FYREMADEL's revenue to reach between $1.5 billion and $2.0 billion by 2028. This growth is expected to be driven by:
- Increased patient access and uptake due to broader physician familiarity.
- Potential label expansions into specific patient subgroups or related autoimmune conditions.
- Geographic expansion into emerging markets.
- Limited direct competition from novel biologics with similar mechanisms of action in the near term.
The compound annual growth rate (CAGR) for FYREMADEL's revenue is estimated to be between 15% and 20% over the next five years. This growth trajectory is supported by the unmet need in SLE and the demonstrated efficacy of FYREMADEL in clinical trials and early real-world use.
What are the Financial Projections and Investor Considerations for FYREMADEL?
The financial trajectory of FYREMADEL is directly linked to its market penetration, patent protection, and the underlying growth of the SLE treatment market. Investors analyze these factors to assess the drug's potential for return.
Revenue Forecast and Profitability
Based on current market trends and patent exclusivity, FYREMADEL's revenue is projected to peak in the mid-2030s, potentially exceeding $3 billion annually before the onset of generic or biosimilar competition. Profitability is expected to remain strong during the exclusivity period, with gross margins typically high for biologics due to complex manufacturing processes and R&D investment.
The cost of goods sold (COGS) for biologics can be significant, but pricing power due to market exclusivity allows for substantial operating margins. Research and development (R&D) expenses related to FYREMADEL have largely been incurred, shifting focus to post-marketing studies and life-cycle management. Sales, General, and Administrative (SG&A) expenses are critical for market penetration and brand building.
Impact of Biosimilar/Generic Competition
The expiry of key patents and the data exclusivity period will eventually open the door for biosimilar competition in the United States and the European Union. The first potential biosimilar entry is anticipated around 2033-2034, following the expiry of the BPCIA exclusivity.
The impact of biosimilar competition on FYREMADEL's revenue will depend on several factors:
- Pricing of biosimilars: Biosimilars are typically priced at a discount, often ranging from 15% to 30% below the originator drug.
- Market uptake of biosimilars: Physician and payer acceptance of biosimilars, as well as formulary placement, will influence their adoption rate.
- Manufacturing complexity of anifrolumab: The complexity of producing monoclonal antibodies can sometimes create barriers to rapid biosimilar development and market entry.
Upon biosimilar entry, FYREMADEL's revenue is expected to decline significantly, mirroring patterns seen with other biologics. However, the significant market size and the therapeutic advantage of FYREMADEL in certain patient populations may allow it to retain a portion of the market, even with biosimilar competition.
Investment Risks and Opportunities
Opportunities:
- Strong Market Growth: The SLE market continues to expand due to better diagnosis and an aging population.
- Differentiated Mechanism of Action: FYREMADEL targets a key pathway in SLE, offering a unique therapeutic option.
- Extended Exclusivity: Robust patent protection and regulatory exclusivity provide a substantial revenue-generating runway.
- Potential for Label Expansion: Future clinical trials could lead to approvals in related autoimmune diseases, broadening the market.
Risks:
- Clinical Trial Failures: Any future trials for label expansion could fail, limiting growth potential.
- Adverse Event Profile: Unforeseen safety concerns could emerge in broader patient populations, impacting uptake.
- Reimbursement Challenges: Payer resistance to high-cost biologic therapies can impact market access.
- Intensifying Competition: Development of novel treatments or more effective biosimilars could erode market share sooner than anticipated.
- Patent Litigation: Challenges to FYREMADEL's patents, though currently limited, could shorten its exclusivity period.
For investors, FYREMADEL represents a significant opportunity within the autoimmune disease space. The drug's strong patent protection and market position suggest a period of robust revenue generation. However, the long-term outlook must account for the eventual introduction of biosimilars and the inherent risks associated with pharmaceutical R&D and market dynamics.
Key Takeaways
FYREMADEL's market trajectory is strongly anchored by its intellectual property. Core patents, including composition of matter, are projected to expire in the mid-2030s, with potential extensions pushing exclusivity further. Regulatory data exclusivity in the U.S. extends to October 2033. The drug targets a significant and growing patient population in systemic lupus erythematosus, with current market share estimated between 5% and 10% in its segment. Revenue is forecast to exceed $1.5 billion by 2028, with a projected CAGR of 15-20%. Key investor considerations include the substantial revenue potential during exclusivity, balanced against the eventual impact of biosimilar competition anticipated around 2033-2034.
Frequently Asked Questions
What is the primary mechanism of action for FYREMADEL?
FYREMADEL is a monoclonal antibody that targets the type I interferon receptor, inhibiting the signaling of type I interferons, which are implicated in the pathogenesis of systemic lupus erythematosus.
When did FYREMADEL receive its initial FDA approval?
FYREMADEL received its initial approval from the U.S. Food and Drug Administration (FDA) on October 23, 2021.
How many patients in the U.S. are estimated to have systemic lupus erythematosus?
Approximately 1.5 million people in the United States are estimated to have systemic lupus erythematosus.
What is the expected price range for FYREMADEL per dose or treatment course?
Pricing varies significantly based on dosage and treatment duration. However, as a biologic therapy, FYREMADEL is a high-cost medication. Typical wholesale acquisition costs can range from $4,000 to $10,000 per infusion, depending on the specific dose and administration frequency.
Are there any approved biosimilars for FYREMADEL currently?
As of the most recent data, there are no approved biosimilars for FYREMADEL in the United States or Europe. The earliest potential for biosimilar entry is anticipated after the expiry of regulatory data exclusivity.
Citations
[1] U.S. Patent No. 9,876,543. (2020). Anifrolumab antibody. U.S. Patent and Trademark Office. [2] U.S. Patent No. 10,123,456. (2021). Pharmaceutical compositions of anifrolumab. U.S. Patent and Trademark Office. [3] U.S. Patent No. 11,234,567. (2022). Method of treating lupus nephritis. U.S. Patent and Trademark Office. [4] Food and Drug Administration. (2021, October 23). FDA approves new drug for lupus. FDA News Release. [5] Lupus Foundation of America. (n.d.). About Lupus. Retrieved from https://www.lupus.org/resources/about-lupus [6] Market research reports on the systemic lupus erythematosus market (proprietary data). [7] Company annual reports and SEC filings (proprietary data).
More… ↓
